<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00613964</url>
  </required_header>
  <id_info>
    <org_study_id>Cardiol001</org_study_id>
    <nct_id>NCT00613964</nct_id>
  </id_info>
  <brief_title>The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure</brief_title>
  <official_title>The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nara Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nara Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carperitide (alpha-human atrial natriuretic peptide) improves systemic hemodynamics in
      patients with heart failure through a vasodilatory action, a natriuretic action, and
      inhibition of the renin-angiotensin-aldosterone system and has been widely-used in Japan.
      However, a paucity of report is available on the effects of carperitide on short and
      long-term prognosis in patients with both cardiac and renal failure. The purpose of this
      study is to evaluate the effects of carperitide therapy on short and long-term prognosis in
      patients with both cardiac and renal failure, in comparison with standard therapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Unexpected rehospitalization for cardiovascular events, uremic symptom, initiation of maintenance dialysis, and kidney transplantation</measure>
    <time_frame>at 6 months and 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>at discharge, 6 months, and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sudden death</measure>
    <time_frame>at discharge, 6 months, and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>at discharge, 6 months, and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma B-type natriuretic peptide concentration</measure>
    <time_frame>at discharge, 6 months, and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated GFR</measure>
    <time_frame>at discharge, 6 months, and 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Heart Failure</condition>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard heart failure therapy excluding carperitide administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carperitide Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Addition of carperitide administration to standard heart failure therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carperitide heart failure therapy</intervention_name>
    <description>carperitide(alpha-human atrial natriuretic peptide, 0.025-0.05Î¼g/kg/min)</description>
    <arm_group_label>Carperitide Therapy</arm_group_label>
    <other_name>Loop-diuretics etc + HANP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard heart failure therapy</intervention_name>
    <description>Loop diuretics, Aldosterone blockers, Beta blockers, ACE inhibitors, Angiotensin receptor blockers, Nitrates, digitalis</description>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heart failure of any etiology, diagnosed according to Framingham criteria

          -  Estimated GFR &lt;/= 60 ml/min/1.73 m2)

        Exclusion Criteria:

          -  Severe heart failure required percutaneous cardiopulmonary bypass support (PCPS)

          -  End-stage renal failure on maintenance dialysis

          -  Severe hepatic dysfunction

          -  Severe anemia

          -  Allergic history of carperitide

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshihiko Saito, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>First Department of Internal Medicine, Nara Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Department of Internal Medicine, Nara Medical University</name>
      <address>
        <city>Nara</city>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2008</study_first_submitted>
  <study_first_submitted_qc>January 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <last_update_submitted>July 20, 2011</last_update_submitted>
  <last_update_submitted_qc>July 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Yoshihiko Saito</name_title>
    <organization>First Department of Internal Medicine, Nara medical university</organization>
  </responsible_party>
  <keyword>Natriuretic Peptides</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Renal Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

